Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Merrell Dow Pharmacueticals Inc.

George Ku

Albert A Carr

Ronald C Bernotas

Craig E Thomas

Niall S Doherty

Boyd Lynn Harrison

Roger A Parker

David M Stemerick

Richard L Jackson

Simon J Mao

Christopher R Dalton

Scott B Meikrantz

Benzenesulfonylimine derivatives as inhibitors of IL-1 action

Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1

The present invention is directed to a new class of cyclic nitrones and their use as spin trapping agents.

Cyclic nitrones

Cyclic nitrone compounds useful in treating stroke

Cyclic nitrones, pharmaceutical compositions thereof and their use in

The present invention relates to a method of lowering plasma triglycerides in a patient in need thereof comprising administering to said patient an effective hypotriglyceridemic amount of a bis(3,5-di-alkyl-4-hydroxyphenylthio)methane.

Hypotriglyceridemic use of certain bis

This invention relates to novel aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions.

Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds

This invention relates to the method of using aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds to treat interleukin-1 mediated conditions.

Method of using aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid

Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Method of inhibiting interleukin-1 release

Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-disobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Methods useful for inhibiting the release of Interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1 mediated inflammation, comprising administration of an effective amount of an alkylidenedithiobis(substituted)phenol, preferably, 4,4'-(isopropylidenedithio(bis(2,6-di-tert-butyl) phenol, generically known as probucol.

Growing community of inventors

West Chester, OH, United States of America

George Ku